glp-1 demand Impact of Drug Adoption on Consumer Food New Demand in an Old

Our findings strongly suggest the answer is yes. Primes recent real-world study found 63% of high-potency GLP-1 (Wegovy or Zepbound) users who started treatment in Q1 2024 are still taking their medication after a year

Consumers using the meds were more likely to be between 40 and 64 years of age

Why guys are...

Starting price of $149 offers improved accessibility compared to market prices of brand-name medications which can be 8x higher Noom stands behind its program with a Taper-Off Guarantee offering a pathway off supposedly forever medications. Solves the biggest real-world challenges with GLP-1s poor persistence and lean muscle loss by pairing the medication with Noom GLP-1 Companion with Muscle DefenseTM

Development of a ligand-based proximity labeling strategy enables interrogation of the native cell membrane interactome for the GLP-1 receptor in two cell types, revealing new regulators of receptor-mediated signaling and cell responses.

14g of protein per serving